Cipla Ltd Analyst Rating
based on 36 analysts
61.11%
Buy
19.44%
Hold
19.44%
Sell
Based on 36 analysts offering long term price targets for Cipla Ltd. An average target of ₹1629.03
Source: S&P Global Market Intelligence
Cipla Ltd Share analysis
Cipla Ltd price forecast by 36 analysts
Upside of10.66%
High
₹1960
Target
₹1629.03
Low
₹1204
Cipla Ltd target price ₹1629.03, a slight upside of 10.66% compared to current price of ₹1476.05. According to 36 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Cipla Ltd revenue growth forecast
Expected growth rate Q1, FY2026:16.64%
Forecast
Actual
Including amortisation and stock based compensations
Cipla Ltd EPS growth forecast
EPS estimate Q1, FY2026:25.37%
Forecast
Actual
Source: S&P Global Market Intelligence
Cipla Ltd Performance
Day's Low
Day's High
₹1,458.8Day's Price Range₹1,49152 Week's Low
52 Week's High
₹1,205.8552-Week Price Range₹1,702.05
| Returns % | |
| 1 Month Return | -2.08 % |
| 3 Month Return | -11.22 % |
| 1 Year Return | + 18.24 % |
| Market Stats | |
| Previous Close | ₹1,472.05 |
| Open | ₹1,473.95 |
| Volume | 7.61L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹1,18,884.82Cr |
Cipla Ltd Key Statistics
| P/E Ratio | 27.18 |
| PEG Ratio | 2.15 |
| Market Cap | ₹1,18,884.82 Cr |
| P/B Ratio | 4.31 |
| EPS | 51.47 |
| Dividend Yield | 0.87 |
| Sector | Pharmaceuticals |
| ROE | 15.5 |
Cipla Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹1,18,884.82 Cr | 42.93% | 0.50 | ₹4,155 Cr | ₹25,774 Cr | |
| HOLD | ₹1,55,212.84 Cr | 44.67% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,16,318.47 Cr | 53.62% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| HOLD | ₹40,334.16 Cr | 3.52% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹29,198.95 Cr | -0.52% | 0.50 | ₹772 Cr | ₹5,664 Cr |
About Cipla Ltd
Cipla's operations include manufacturing, marketing, and distribution of pharmaceuticals, biotechnology, and consumer healthcare products. Its top products include respiratory, anti-infectives, cardiovascular, and oncology drugs. Popular brands include Asthalin, Cipcal, Cifran, and Erythromycin. Cipla also manufactures nutraceuticals, herbal products, and over-the-counter medicines.
Share Price: ₹1476.05 per share as on 23 Dec, 2024 04:01 PM
Market Capitalisation: ₹1,18,884.82Cr as of today
Revenue: ₹6,961.22Cr as on September 2024 (Q3 24)
Net Profit: ₹1,306.02Cr as on September 2024 (Q3 24)
Listing date: 03 Nov, 1994
Chairperson Name: Y K Hamied
| Organisation | Cipla Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Cipla Ltd
Cipla Faces GST Penalty Over Credit Claim - 20 Dec, 2024
Cipla Ltd has been fined ₹1,11,94,324 by the GST authority for allegedly claiming inadmissible TRAN-1 credit. The company contests the penalty and plans to appeal, asserting no material impact on its financials or operations.Cipla Launches Innovative Asthma Screening App - 19 Dec, 2024
Cipla Limited has introduced CipAir, an AI-driven mobile application for asthma screening, enhancing patient access to timely diagnosis and management of asthma.Citi Bullish on Cipla with Target Price of Rs 1800 - 18 Dec, 2024
Citi has assigned a BUY rating to Cipla, projecting a target price of Rs 1800. The firm anticipates significant revenue from potential Gattex product approvals, estimating annual revenues of USD 80-140 million if successful.Cipla Shares Surge After Kotak Upgrade - 17 Dec, 2024
Cipla shares surged after Kotak Institutional Equities upgraded the stock to 'Buy' from 'Add', setting a target price of ₹1,725, citing strong fundamentals and growth potential despite some challenges.Cipla Secures Approval for Inhaled Insulin Afrezza - 11 Dec, 2024
Cipla has obtained regulatory approval from CDSCO to exclusively distribute Afrezza, a rapid-acting inhaled insulin, enhancing diabetes management options in India. This innovative product aims to empower patients by providing a non-injectable solution for both type 1 and type 2 diabetes, starting to work within 12 minutes.Cipla Gains Analyst Confidence Post Goa Plant Approval - 10 Dec, 2024
Despite a recent decline in Cipla shares, analysts remain optimistic following the approval of its Goa plant, paving the way for the launch of Abraxane. Citi maintains a buy rating with a price target of Rs 1,830, highlighting the drug's significance to Cipla's growth prospects.Cipla Faces GST Penalty but Sees No Financial Impact - 07 Dec, 2024
Cipla Limited received a GST penalty order of INR 109.5 million for alleged improper credit note issuance. The company plans to appeal, asserting the order is unjustified and has no material impact on its financials.Cipla Faces GST Penalty Amid Positive Growth Outlook - 04 Dec, 2024
Cipla has been charged a ₹10.95 crore GST penalty for tax irregularities but plans to appeal. Meanwhile, Geojit maintains a BUY rating with a target of Rs. 1,695, highlighting revenue growth across various markets.Cipla Founders Exit with Significant Stake Sale - 03 Dec, 2024
Cipla founders Samina and Rumana Hamied sold their entire 1.72% stake for Rs 2,111 crore, attracting investments from various prominent institutions and funds.Promoters Sell 1.72% Stake in Cipla - 02 Dec, 2024
Promoters Samina and Rumana Hamied sold a combined 1.72% stake in Cipla for Rs 2,111 crore, reducing their holding to 29.2%. The stock price fell 1.36% following the sale.Cipla Promoters Plan Major Stake Sale Amid Stock Gains - 29 Nov, 2024
Cipla's stock gained 3.13% to Rs 1,539.40, boosting market cap. Promoters plan to sell 1.72% stake for Rs 2,000 crore, while analysts upgrade the stock to 'Buy' with a target of Rs 1,730, highlighting strong financials and upcoming launches.Cipla Faces GST Penalty, Plans to Appeal - 28 Nov, 2024
Cipla Limited has been imposed a ₹53 lakh penalty by the GST Authority for claiming inadmissible TRAN-1 credit. The company deems the penalty unjustified and intends to appeal. There is no material impact on its financials or operations.InCred Upgrades Cipla to Overweight Rating - 27 Nov, 2024
InCred Equities has upgraded its stance on Cipla Ltd to overweight, assigning an 'add' rating with a target price of Rs 1,640, citing expected growth from the approval of its Goa plant.
Insights on Cipla Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTFII Holding Up
Foreign Institutions have increased holdings from 27.77% to 28.74% in Sep 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 6.41K Cr → 7.24K Cr (in ₹), with an average increase of 5.9% per quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, 939.04 Cr → 1.30K Cr (in ₹), with an average increase of 14.9% per quarter
- POSITIVE IMPACT
Price Rise
In the last 7 days, CIPLA stock has moved up by 1.6%
NO EFFECTAgainst Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 128.3% return, outperforming this stock by 66.4%
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 51.3% return, outperforming this stock by 33.1%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 30.86% of holdings in Sep 2024 quarter
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 16.30% to 16.08% in Sep 2024 quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 17.59% to 17.44% in Sep 2024 quarter
News
Weight-loss Drugs: A Game Changer for India's Top Pharma Companies
Cipla, one of Indias most well-established pharmaceutical companies, is focusing its efforts on the development of a generic version of Wegovy (semaglutide), an obesity treatment developed by Novo Nordisk. Cipla plans to bring a more affordable alternative to the Indian market, which could significantly increase access to treatment for those struggling with obesity.23 Dec, 2024 10:29 AMIndia’s CDSCO Approves 19 New Drugs in 2024
Cipla Ltd also got the CDSCO approval to market a novel antibiotic - plazomicin, a key development in solving anti-microbial resistance. Cipla USA Inc., a subsidiary of Cipla, holds the patent for plazomicin sulfate, administered once daily. The company possesses global rights for this molecule, excluding Greater China, and is the innovator of the ZEMDRI brand. Orchid Pharma has teamed up with domestic major Cipla Ltd to sell the drug in various markets.22 Dec, 2024 09:38 AMCipla's Big Bet on Diabetes Care with Inhalable Insulin
Cipla, Indias third largest drug maker by market share, is taking an audacious bet on this enormous unmet medical need. Recently, the company announced that it has received the government approval to sell Afrezza, an insulin that can be inhaled from the mouth.21 Dec, 2024 01:08 AMCipla Ltd Financials
Index Inclusions
Cipla Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 30.86% | ||
| Foreign Institutions | 28.74% | 3.49 | |
| Mutual Funds | 17.44% | ||
| Retail Investors | 16.08% | ||
| Others | 6.89% |
Cipla Ltd Key Indicators
Cipla Ltd Valuation
Cipla Ltd in the last 5 years
Lowest (18.11x)
March 19, 2020
Today (27.18x)
December 19, 2024
Industry (56.23x)
December 19, 2024
Highest (42.80x)
January 23, 2018
Cipla Ltd Earnings and Dividends
Cipla Ltd Earnings Results
Cipla Ltd’s net profit jumped 15.18% since last year same period to ₹1,302.53Cr in the Q2 2024-2025. On a quarterly growth basis, Cipla Ltd has generated 10.61% jump in its net profits since last 3-months.
Read More about Earnings ResultsCipla Ltd Dividends May,2024
In the quarter ending March 2024, Cipla Ltd has declared dividend of ₹13 - translating a dividend yield of 1.46%.
Read More about Dividends
Cipla Ltd Technicals Summary
Bearish
Neutral
Bullish
Cipla Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Cipla Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Cipla Ltd shares.
Cipla Ltd (CIPLA) share price today is ₹1476.05
Cipla Ltd is listed on NSE
Cipla Ltd is listed on BSE
- Today’s highest price of Cipla Ltd is ₹1491.
- Today’s lowest price of Cipla Ltd is ₹1458.8.
PE Ratio of Cipla Ltd is 27.18
PE ratio = Cipla Ltd Market price per share / Cipla Ltd Earnings per share
Today’s traded volume of Cipla Ltd(CIPLA) is 7.61L.
Today’s market capitalisation of Cipla Ltd(CIPLA) is ₹118884.82Cr.
| Cipla Ltd(CIPLA | Price |
|---|---|
52 Week High | ₹1702.05 |
52 Week Low | ₹1205.85 |
Cipla Ltd(CIPLA) share price is ₹1476.05. It is down -13.28% from its 52 Week High price of ₹1702.05
Cipla Ltd(CIPLA) share price is ₹1476.05. It is up 22.41% from its 52 Week Low price of ₹1205.85
| Cipla Ltd(CIPLA | Returns |
|---|---|
1 Day Returns | 4% |
1 Month Returns | -2.08% |
3 Month Returns | -11.22% |
1 Year Returns | 18.24% |